Published by The Western PA Healthcare News Team
Updated on December 7, 2022
Significant progress has been achieved in advancing the utilization of cannabis and cannabinoid products for medical purposes. Nevertheless, a formidable barrier stands in the way of their widespread acceptance: the FDA.
While there exists a procedure for cannabinoid products to seek FDA approval, it is intricate and often perplexing to navigate. Until this process is simplified and clarified through a more transparent regulatory framework, consumers will continue to be deprived of the care they rightfully deserve.
Challenges Posed by Current FDA Regulations on Cannabinoid Products
Present FDA regulations impose numerous constraints on the marketing and distribution of cannabis-derived products. This is partly due to the intricate legal status of cannabis at the federal level, compounded by the FDA’s guidelines which pose additional hurdles. For instance, cannabis products have not been sanctioned by the FDA for prescription as medicines to treat specific diseases or conditions. Moreover, products containing cannabinoids as active ingredients, despite their potential benefits, cannot be marketed as food or dietary supplements.
At present, only one cannabis-derived product, Epidiolex, which contains CBD, holds FDA approval, alongside three cannabis-related products—Marinol, Syndros, and Cesamet—that contain synthetic delta-9-THC. However, these approvals are limited to extremely specific circumstances, primarily for managing severe seizures or chemotherapy-induced nausea.
The Imperative of Clinical Trials for Cannabinoid Products
Establishing a more transparent regulatory framework for cannabinoid products would facilitate more cannabis-derived drugs to undergo clinical trials and secure FDA approval. Clinical trials are a crucial prerequisite for any drug to enter the market, providing researchers with an opportunity to assess the drug’s efficacy and safety under controlled conditions, ensuring it delivers the intended therapeutic effects without posing significant risks to the public.
While there are several unapproved cannabinoid products available on the market, cannabis-derived drugs could serve a wider patient population if subjected to rigorous clinical trials. Although unapproved cannabinoid products may not inherently pose safety concerns, FDA approval signifies that they have undergone comprehensive testing to verify their effectiveness and safety.
The Future Landscape of Cannabinoid Regulation
Encouragingly, the FDA has expressed willingness to evaluate any cannabinoid products seeking FDA approval through proper clinical trials. Nonetheless, the existing system presents a series of challenges that companies must navigate to even initiate trials. For instance, companies must obtain their products from an FDA-approved cultivator, often the NIDA Drug Supply Program. Additionally, independent cultivators must seek DEA approval to grow and distribute marijuana for research purposes, further complicating the process.
To pave the way for cannabinoid products to undergo clinical trials and secure FDA approval, it necessitates the involvement of individuals within the FDA who possess expertise in cannabis and cannabis-derived products. Fortunately, the recent hiring of cannabis policy expert Norman Birenbaum by the FDA indicates a commitment to advancing cannabis policy. Under Birenbaum’s guidance, it is hoped that the FDA will gain a deeper understanding of the necessary regulatory framework to streamline the approval process.
Cannabinoid products have demonstrated their potential to alleviate suffering in various profound ways. However, until the FDA establishes a more transparent regulatory framework for their approval, they will remain constrained from realizing their full therapeutic potential. Presently, cannabinoids are burdened with navigating numerous arbitrary obstacles stemming from their legal status and societal stigma. Only with the guidance of a cannabinoid expert like Birenbaum can we overcome these barriers.
Jorge Olson is the co-founder and CMO of two publicly traded companies, Hempacco (HPCO) and Green Globe International (GGII). Born in Tijuana, Mexico, without access to running water or electricity, Olson overcame numerous challenges to achieve success. Today, he is not only an author of business and inspirational books but also a recognized authority in consumer packaged goods, beverages, and wholesale distribution. His partners include prominent entrepreneurs such as Sandro Piancone, as well as notable figures like Cheech and Chong, James Linsey, and Rick Ross.
Published by The Western PA Healthcare News Team
